Skip to main content
TipRanks
Go Ultimate75% OFF

Entheon Biomedical (1XU) Stock Price & Analysis

0 Followers

1XU Stock Chart & Stats

€0.03€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.028€0.029€0.03€0.031Oct 20Nov 3Nov 12
Day’s Range
EUR 0.03 - EUR 0.03
52-Week Range
EUR 0.02 - EUR 0.10
Previous Close
EUR 0.03
Volume
N/A
Average Volume (3M)
25
Market Cap
EUR 440.55K
Enterprise Value
EUR 1.06M
Total Cash (Recent Filing)
EUR 321.83K
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
-0.78
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The absence of reported debt limits interest obligations and reduces refinancing pressure while the company funds development activities. This gives management more flexibility than a leveraged biotechnology peer, although the benefit is tempered by recurring losses and a small capital base.

Focused Therapeutic Development

A focused research strategy can concentrate scarce resources on a defined unmet-need area rather than spreading investment across unrelated programs. Work on DMT-based candidates and supporting clinical and regulatory activities provides a coherent pathway toward potential medical applications.

Improved Cash Burn Versus Earlier Years

The improvement from the extreme cash-burn levels of 2021–2022 indicates some progress in controlling cash consumption over the broader period. If maintained, better cash discipline could extend the funding runway, though recent deterioration means this remains an uneven strength.

Bears Say

No Recent Revenue

Zero recent revenue shows that the company has not yet converted its research activities into a commercial income stream. Without recurring sales, progress depends on advancing candidates toward medical use, making future operating performance highly dependent on development execution.

Persistent Operating Losses

Recurring operating and net losses indicate that the current business model has not reached sustainable profitability. Continued losses reduce retained capital and leave limited evidence of self-funded growth, increasing the importance of successful development milestones and disciplined spending.

Ongoing Cash Funding Requirement

Persistent negative operating and free cash flow means the company continues to consume cash rather than generate it internally. That can constrain research progress or require additional external funding, while repeated financing needs may pressure financial flexibility if losses continue.

Entheon Biomedical News

1XU FAQ

What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was €0.02 and its highest was €0.10 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is €440.55K.
When is Entheon Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Jul 20, 2026. The company reported €0.011 earnings per share for the quarter.
Is Entheon Biomedical overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of €0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in DE:1XU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology